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Binding to serine 65-phosphorylated ubiquitin
primes Parkin for optimal PINK1-dependent
phosphorylation and activation
Agne Kazlauskaite1, R Julio Martínez-Torres1, Scott Wilkie2, Atul Kumar1, Julien Peltier1, Alba
Gonzalez1, Clare Johnson1, Jinwei Zhang1, Anthony G Hope2, Mark Peggie1, Matthias Trost1, Daan MF
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Abstract
Mutations in the mitochondrial protein kinase PINK1 are associ-
ated with autosomal recessive Parkinson disease (PD). We and
other groups have reported that PINK1 activates Parkin E3 ligase
activity both directly via phosphorylation of Parkin serine 65
(Ser65)—which lies within its ubiquitin-like domain (Ubl)—and
indirectly through phosphorylation of ubiquitin at Ser65. How
Ser65-phosphorylated ubiquitin (ubiquitinPhospho-Ser65) contributes
to Parkin activation is currently unknown. Here, we demonstrate
that ubiquitinPhospho-Ser65 binding to Parkin dramatically increases
the rate and stoichiometry of Parkin phosphorylation at Ser65 by
PINK1 in vitro. Analysis of the Parkin structure, corroborated by
site-directed mutagenesis, shows that the conserved His302 and
Lys151 residues play a critical role in binding of ubiquitinPhospho-Ser65,
thereby promoting Parkin Ser65 phosphorylation and activation of
its E3 ligase activity in vitro. Mutation of His302 markedly inhibits
Parkin Ser65 phosphorylation at the mitochondria, which is associ-
ated with a marked reduction in its E3 ligase activity following
mitochondrial depolarisation. We show that the binding of
ubiquitinPhospho-Ser65 to Parkin disrupts the interaction between
the Ubl domain and C-terminal region, thereby increasing the
accessibility of Parkin Ser65. Finally, purified Parkin maximally
phosphorylated at Ser65 in vitro cannot be further activated by the
addition of ubiquitinPhospho-Ser65. Our results thus suggest that a
major role of ubiquitinPhospho-Ser65 is to promote PINK1-mediated
phosphorylation of Parkin at Ser65, leading to maximal activation
of Parkin E3 ligase activity. His302 and Lys151 are likely to line a
phospho-Ser65-binding pocket on the surface of Parkin that is critical
for the ubiquitinPhospho-Ser65 interaction. This study provides new
mechanistic insights into Parkin activation by ubiquitinPhospho-Ser65,
which could aid in the development of Parkin activators that
mimic the effect of ubiquitinPhospho-Ser65.
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Introduction
Mutations in genes encoding the protein kinase PTEN-induced
kinase 1 (PINK1) and the ubiquitin E3 ligase, Parkin, are causal for
early-onset Parkinson’s disease (PD) [1,2]. Multiple lines of
evidence indicate that these enzymes operate in a common mito-
chondrial signal transduction pathway [3,4]. In mammalian cells,
PINK1 is activated upon mitochondrial membrane potential depolar-
isation that can be induced by mitochondrial uncouplers, for exam-
ple carbonyl cyanide m-chlorophenylhydrazone (CCCP), leading to
mitochondrial recruitment and activation of Parkin [5–10].
Biochemical and structural analysis has revealed that Parkin is auto-
inhibited and that conformational change would be required for its
activation [11–14]. Our own laboratory and that of others have
revealed that PINK1 directly phosphorylates Parkin at serine 65
(Ser65) within its N-terminal ubiquitin-like (Ubl) domain [9,15] as
well as the equivalent Ser65 residue of ubiquitin [16–19] and the
phosphorylation of both of these residues is required for maximal
activation of Parkin E3 ligase activity [16–19]. However, the mecha-
nism of how Ser65-phosphorylated ubiquitin (ubiquitinPhospho-Ser65)
contributes to Parkin activation remains unknown.
Here, we report the discovery that ubiquitinPhospho-Ser65 can
prime Parkin to be efficiently phosphorylated by PINK1 at Ser65 of
its Ubl domain, which in turn leads to maximal activation of Parkin
E3 ligase activity. We have investigated the interaction between
Parkin and ubiquitinPhospho-Ser65 through biophysical and mutational
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analyses and identified that the conserved Parkin His302 and
Lys151 residues play a critical role in ubiquitinPhospho-Ser65 binding
to Parkin and for Ubl Ser65 phosphorylation by PINK1. Furthermore,
we show that a His302Ala (H302A) mutation prevents optimal acti-
vation of Parkin by ubiquitinPhospho-Ser65 in vitro. In cell-based stud-
ies, we confirm that the H302A mutant leads to impaired Parkin
Ser65 phosphorylation upon PINK1 activation induced by CCCP and
moreover, immunofluorescence studies reveal that the Ser65-phos-
phorylated H302A mutant mainly resides in the cytosol in contrast
to strong mitochondrial accumulation of Ser65-phosphorylated wild-
type (WT) Parkin. We further show that maximally phosphorylated
Ser65-WT Parkin exhibits robust E3 ligase activity that does not
change following the addition of ubiquitinPhospho-Ser65. Overall, our
data provide new insights into the activation of Parkin and suggest
a two-step activation model wherein during Step 1, ubiquitinPhospho-Ser65
binds to Parkin inducing a conformational change of the Ubl domain
that exposes Ser65 and in Step 2, PINK1 phosphorylates the Ubl
domain more efficiently leading to maximal Parkin activation.
Results and Discussion
UbiquitinPhospho-Ser65 primes Parkin Ser65 for phosphorylation
by PINK1
In previous work, we reported that PINK1 directly phosphorylates
full-length Parkin at Ser65 within its Ubl domain. The rate of phos-
phorylation of full-length Parkin was substantially lower than that of
the isolated Ubl domain, indicating that the Ser65 residue may be
partially accessible in the full-length autoinhibited conformation [9].
Strikingly, we observed that the addition of increasing amounts of
ubiquitinPhospho-Ser65 markedly increased the rate as well as the stoi-
chiometry of phosphorylation of the Parkin Ubl Ser65 residue reach-
ing ~0.9 in the presence of 3-fold excess of ubiquitinPhospho-Ser65
relative to Parkin, compared to ~0.2 without (left panel, Fig 1A). In
contrast, we observed no enhancement of phosphorylation of Parkin
by PINK1 in the presence of a non-phosphorylatable Ser65Ala
mutant of ubiquitin (middle panel, Fig 1A). Addition of increasing
amounts of wild-type ubiquitin led to moderate enhancement of
Parkin phosphorylation due to PINK1 phosphorylating ubiquitin and
generating ubiquitinPhospho-Ser65 during the kinase reaction, which
was confirmed by autoradiography (right panel, Fig 1A). We did not
observe any enhancement of phosphorylation of Parkin S65A as well
as a Ubl-deleted fragment of Parkin (residues 80-465) by PINK1 in
the presence of ubiquitinPhospho-Ser65 (Appendix Fig S1). This indi-
cates that the ubiquitinPhospho-Ser65-mediated enhancement of Parkin
phosphorylation by PINK1 is via Parkin Ubl Ser65 and not due to
phosphorylation of additional sites on Parkin (Appendix Fig S1).
We next investigated the specificity of ubiquitinPhospho-Ser65
enhancement of Parkin phosphorylation by PINK1. In parallel
kinase assays, we compared the effect of ubiquitinPhospho-Ser65 on
PINK1-dependent phosphorylation of Parkin, the isolated Ubl
domain of Parkin and GST-HAX1 (Fig 1B). HAX1 is a mitochondrial
intermembrane protein, which we have recently identified as a good
in vitro substrate of PINK1 although the physiological relevance has
not yet been explored (Appendix Fig S2). We did not observe any
effect of ubiquitinPhospho-Ser65 on PINK1’s ability to phosphorylate
the isolated Ubl domain or HAX1, suggesting that ubiquitinPhospho-
Ser65 does not affect PINK1 activity per se and that it has a specific
effect on modulating the phosphorylation of full-length Parkin
(Fig 1B). We then tested whether isolated Parkin Ubl (1-76) phos-
phorylated at Ser65 (UblPhospho-Ser65) could also affect the stoichio-
metry of phosphorylation of full-length Parkin by PINK1 (Fig 1C). In
contrast to ubiquitinPhospho-Ser65, the addition of UblPhospho-Ser65 did
not affect Parkin phosphorylation, indicating that this effect is
phospho-ubiquitin specific (Fig 1C).
Recent studies have demonstrated that PINK1 can phosphorylate
poly-ubiquitin chains of different linkage types and lengths in addi-
tion to monomeric ubiquitin [19–21]. We therefore investigated
whether ubiquitinPhospho-Ser65-modified ubiquitin chains would have
the same effect as monomeric ubiquitin in promoting Parkin phos-
phorylation by PINK1 (Fig EV1A). Addition of ubiquitin dimers of
each linkage type (Met1, Lys6, Lys11, Lys27, Lys29, Lys33, Lys48
and Lys63) or ubiquitin tetramers with Met1, Lys6, Lys11, Lys29,
Lys33, Lys48 and Lys63 linkages [22,23] led to a similar enhance-
ment of Parkin phosphorylation by PINK1 as that observed follow-
ing the addition of monomeric ubiquitin (Fig EV1A). To date, it is
unknown whether PINK1 can efficiently phosphorylate monoubiqu-
itin attached to a substrates. To address this, we employed a model
monoubiquitylated substrate in which ubiquitin has been C-termi-
nally fused to a Dac tag (a ~28.5-kDa fragment of E. coli penicillin-
binding Protein 5 comprising residues 37-297 that can be captured
and released by binding to ampicillin-Sepharose) [24]. We observed
that Dac-ubiquitin could be readily phosphorylated by PINK1 lead-
ing to enhanced Parkin phosphorylation by PINK1 in a manner simi-
lar to monomeric ubiquitin (Fig EV1B).
▸Figure 1. UbiquitinPhospho-Ser65 primes Parkin for phosphorylation by PINK1.A UbiquitinPhospho-Ser65 enhances Parkin phosphorylation by PINK1. The effects of ubiquitinPhospho-Ser65 (left), wild-type (WT) (right) and Ser65Ala (S65A) (middle)
ubiquitin on Parkin phosphorylation were investigated in a kinase assay. The indicated ubiquitin species was incubated with WT or kinase-inactive (KI) MBP-TcPINK1,
Parkin and Mg2+ [c-32P] ATP for 60 min. Parkin concentration was kept constant, whilst ubiquitin concentration was varied, reaching molar ratios indicated above the
gel. Assays were terminated by the addition of LDS loading buffer, and products were analysed by SDS–PAGE. Proteins were detected by Colloidal Coomassie Blue
staining (top panel), and incorporation of [c-32P] ATP was detected by autoradiography (bottom panel). Data show mean of two trials  s.d., n = 2 for each condition.
B Selectivity of ubiquitinPhospho-Ser65-enhanced Parkin phosphorylation. Under similar conditions, the effects of ubiquitinPhospho-Ser65 on phosphorylation of various PINK1
substrates were assessed in a kinase assay, where equimolar amounts of Parkin, GST-Ubl and GST-HAX1 (all expressed in E. coli) were used in the presence or absence
of ubiquitinPhospho-Ser65 and WT TcPINK1. The incorporation of radioactive [c-32P] ATP into substrate proteins was measured and is displayed above the panels.
Proteins were detected by Colloidal Coomassie Blue staining (top panel), and incorporation of [c-32P] ATP was detected by autoradiography (bottom panel). Broken
dividing lines indicate separate gels; asterisks denote the kinase band. The molecular mass in kDa is indicated. Data show mean of two trials  s.d., n = 2 for each
condition.
C UbiquitinPhospho-Ser65, but not UblPhospho-Ser65, enhances full-length Parkin phosphorylation by PINK1. Kinase assays in the presence or absence of ubiquitinPhospho-Ser65
or UblPhospho-Ser65 were carried out as in (A). Data are representative of two independent experiments.
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In future work, it would be interesting to assess whether (multi)-
monoubiquitylated substrates of Parkin, for example Miro1/2 or
Mitofusin1/2 [25,26], also become phosphorylated at ubiquitin
Ser65 by PINK1 and whether these play a role in aiding in Parkin
activation similar to what we have observed for Dac-ubiquitin. It
would also be critical to define the interactions and timeline of
PINK1 phosphorylation of free monomeric ubiquitin and poly-
ubiquitin as well as mono/poly-ubiquitin attached to substrates that
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Figure 2. Identification of Parkin histidine 302 and lysine 151 as critical residues mediating ubiquitinPhospho-Ser65 interaction and activation of Parkin.
A Structure of Parkin modified from [13] displaying the location of sulphate-containing pockets surrounded by the following residues: Pocket 1 (K161/R163/K211); Pocket
2 (K151/H302/R305/Q316); and Pocket 3 (R455).
B His302 and Lys151 are critical for mediating ubiquitinPhospho-Ser65-enhanced phosphorylation of Parkin by TcPINK1. Wild-type (WT), full-length Parkin or the indicated
Alanine mutant for each residue of the sulphate-containing pocket was incubated with wild-type (WT) MBP-TcPINK1, Parkin and Mg2+ [c-32P] ATP in the presence or
absence of ubiquitinPhospho-Ser65. Proteins were detected by Colloidal Coomassie Blue staining (top panel) and Parkin phosphorylation levels assessed by incorporation
of [c-32P] ATP detected by autoradiography (bottom panel) and displayed above the panel. Data show mean of two trials  s.d., n = 2 for each condition.
C Parkin His302Ala and Lys151Ala mutants disrupt ubiquitinPhospho-Ser65 mediated activation of Parkin E3 ligase activity. WT Parkin and putative Pocket 2 mutants
(K151A, H302A, R305A, Q316A) were assessed for activity via ubiquitylation assays. Each reaction contained 0.05 mM ubiquitin comprising 25 lg of FLAG-ubiquitin
(Boston Biochem) mixed with 5 lg of ubiquitinPhospho-Ser65 or non-phospho-ubiquitin. Parkin activity was evaluated by subjecting ubiquitylation reactions to analysis
by SDS–PAGE and immunoblotting as follows: ubiquitin (anti-FLAG-HRP antibody), Parkin (anti-Parkin antibody) and Miro1 (anti-SUMO1 antibody). Data are
representative of five independent experiments.
D Parkin His302Ala and Lys151Ala mutants hinder Parkin’s ability to interact with ubiquitinPhospho-Ser65 and discharge ubiquitin from a loaded E2. WT Parkin and Pocket 2
mutants were assessed for their ability to discharge ubiquitin from a loaded UbcH7 (E2-Ub) enzyme with or without ubiquitinPhospho-Ser65 or non-phospho-ubiquitin.
Reactions were subjected to SDS–PAGE analysis in the absence of any reducing agent. The activity was assessed by change in UbcH7 (E2)/UbcH7-Ub (E2-Ub) ratio. The
quantification of Coomassie bands was performed by LICOR and is presented above the panel. Data show mean of three trials  s.d., n = 1 for each condition.
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lead to an altered phospho-ubiquitome upon PINK1 and Parkin
activation at the mitochondria.
Identification of Parkin histidine 302 and lysine 151 as key
residues required for binding and maximal activation of Parkin
by ubiquitinPhospho-Ser65
We next investigated the potential interaction sites that enable
ubiquitinPhospho-Ser65 binding and activation of Parkin E3 ligase activ-
ity. Previous structural analysis has highlighted that Parkin contains
a putative phospho-Ser65-binding pocket that we term “Pocket 1”
flanked by residues Lys161 (K161), Arg163 (R163) and Lys211
(K211) that lie within the RING0 domain [13] (Fig 2A). Recent
mutational analysis has suggested that these Pocket 1 residues are
not required for binding of Parkin to ubiquitinPhospho-Ser65 [19]. Upon
inspection of the Parkin structure, we identified two further putative
phospho-Ser65-binding pockets that we term “Pocket 2” and “Pocket
3” (Fig 2A). Pocket 2 is formed from basic residues Lys151 (K151)
(lies in RING0), His302 (H302), Arg305 (R305) and Gln316 (Q316)
(that lie within a small loop between RING1 and IBR), whilst Pocket
3 is formed by a single residue Arg455 (R455) lying within the
RING2 domain (Fig 2A). To explore which residues were critical for
ubiquitinPhospho-Ser65 function towards Parkin, we tested point
mutants of all the putative Parkin pocket residues in a PINK1 kinase
assay in the presence of ubiquitinPhospho-Ser65 (Fig 2B). Strikingly,
these data revealed that mutation of the His302 residue to Ala
(H302A) in Pocket 2 almost completely prevented the ability of
ubiquitinPhospho-Ser65 to enhance Parkin Ser65 phosphorylation by
PINK1 (Fig 2B). Furthermore, the K151A mutation in Pocket 2 also
partially disrupted the ability of ubiquitinPhospho-Ser65 to modify the
PINK1-dependent phosphorylation of Parkin, whereas the R305A
mutant exhibited only a modest effect and Q316A no effect on
ubiquitinPhospho-Ser65-mediated phosphorylation of Parkin Ser65
(Fig 2B). Thermal shift analysis demonstrated that the Parkin
H302A and K151A mutants are as stable as the wild-type Parkin
with no measurable change in thermal stability, indicating no signifi-
cant perturbation of fold or structural integrity (Fig EV2A). Since
our assays are conducted with full-length Parkin and high-resolution
structures of Parkin have been obtained using an N-terminal deleted
fragment of Parkin (RING0-RBR domains), we cannot rule out the
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Figure 3. Parkin His302 and Lys151 are required for optimal binding with ubiquitinPhospho-Ser65.
A Parkin H302A and K151A mutants exhibit marked reduction in binding to ubiquitinPhospho-Ser65 compared to wild-type (WT) Parkin. Isothermal calorimetry analysis of
Parkin WT (left), K151A mutant (middle) and H302A mutant (right) with ubiquitinPhospho-Ser65.
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of two independent experiments.
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possibility that the topology of the ubiquitinPhospho-Ser65 pocket may
be different in the full-length protein structure and involve addi-
tional amino acids not evident from the RING0-RBR structures.
Nevertheless, our analysis strongly suggests a key role for H302 and
K151 in ubiquitinPhospho-Ser65 action towards Parkin. Consistent with
an important role, the H302 and K151 residues are highly
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Figure 5. UbiquitinPhospho-Ser65-mediated disruption of the Ubl domain with DUbl Parkin is dependent on residue His302.
An AlphaScreenTM binding assay of Parkin Ubl domain and C-terminus of Parkin were established. GST-Ubl (residues 1-76) and wild-type C-terminal Parkin-biotin (residues
80-465) were incubated with streptavidin-coated donor beads and glutathione acceptor beads for 60 min.
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Data information: Data show mean of one trial  s.d., n = 3 for each condition (A–D).
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conserved in multiple species of Parkin we have analysed (Appendix
Fig S3).
We next investigated the critical requirement of the H302 residue
in ubiquitinPhospho-Ser65-mediated activation of Parkin E3 ligase
activity. We have previously elaborated a robust Parkin E3 ligase
activity that monitors the formation of free poly-ubiquitin chains, as
well as the multi-monoubiquitylation of the substrate Miro1 [26].
Employing this assay, we observe marked activation of full-length
Parkin E3 ligase activity when incubated with molar excess amounts
of ubiquitinPhospho-Ser65 as judged by the formation of free poly-
ubiquitin chains, Miro1 multi-monoubiquitylation and Parkin
autoubiquitylation (lanes 1–2, Fig 2C). Consistent with our phos-
phorylation assay analysis, we observed significant inhibition of the
ability of ubiquitinPhospho-Ser65 to activate Parkin following mutation
of His302, emphasised by a complete absence of Miro1 ubiquityla-
tion and substantial reduction of free poly-ubiquitin chain formation
and Parkin autoubiquitylation (lanes 5–6, Fig 2C). In contrast, the
H302A mutant did not disrupt the ability of TcPINK1 to induce
Parkin E3 ligase activity via phosphorylation of Ubl Ser65 in the
presence of a non-phosphorylatable Ser65Ala mutant of ubiquitin,
suggesting that the H302A mutant is not significantly perturbing the
conformation of Parkin and instead is selectively affecting ubiqu-
itinPhospho-Ser65 interaction (Fig EV2B). Consistent with our previous
phosphorylation analysis (Fig 2B), the K151A mutant exhibited
partial reduction in Parkin activity as judged by Parkin autoubiqui-
tylation and free poly-ubiquitin chain formation (lanes 3–4, Fig 2C)
and the R305A mutant exhibited modest effects on Parkin activation
upon addition of ubiquitinPhospho-Ser65 (lanes 7–8, Fig 2C).
We next assessed the impact of the Pocket 2 mutants on Parkin
activity using an E2 discharge assay that measures the ability of
ubiquitinPhospho-Ser65 to stimulate the discharge of the ubiquitin-
loaded E2, UbcH7, by Parkin. Whilst the addition of ubiqui-
tinPhospho-Ser65 but not ubiquitin led to maximal E2 ubiquitin
discharge by wild-type Parkin (lanes 4 and 5, Fig 2D), this was
completely disrupted by the H302A mutant (lanes 8 and 9, Fig 2D)
and partially by mutations of K151A (lanes 6 and 7, Fig 2D) and
R305A (lanes 10 and 11, Fig 2D).
To demonstrate any direct involvement of Pocket 2 residues in
binding of ubiquitinPhospho-Ser65, we undertook isothermal titration
calorimetry (ITC) analysis of ubiquitinPhospho-Ser65 with full-length
wild-type Parkin and the two most deleterious mutants H302A and
K151A based on our previous analyses (Fig 2B–D). Similar to a
recent study, we found wild-type Parkin binds ubiquitinPhospho-Ser65
with a Kd of ~156 nM affinity (left panel, Fig 3A and B) [19]. In
contrast, we observed the K151A mutant binds ubiquitinPhospho-Ser65
with 45-fold lower affinity (Kd of ~7 lM) than wild-type Parkin
(middle panel, Fig 3A and B) and the H302A mutant exerted a more
dramatic effect with a 265-fold reduced affinity of binding ubiqu-
itinPhospho-Ser65 (Kd of ~42 lM) (right panel Fig 3A and B). Overall,
this indicates that His302 and Lys151 residues are required for opti-
mal binding of ubiquitinPhospho-Ser65.
We also undertook complementary gel filtration analysis to
assess for heterodimeric complex formation of wild-type Parkin with
ubiquitinPhospho-Ser65. We exploited the above-described N-terminal
Dac tag ubiquitin since this retains monomeric properties and
enables visualisation of binding due to a large change in molecular
weight that is easily visible by gel filtration analysis [24]. We next
produced a tagged fusion protein of Dac-ubiquitinPhospho-Ser65 or
non-phosphorylated ubiquitin. Size-exclusion chromatography using
a Superdex 200 Increase (10/300 GL) column was employed with
250 ll of purified protein at a concentration of 0.8 mg/ml. Incubation
of Dac-ubiquitin with wild-type Parkin revealed no strong interaction
and two separate peaks (Fig EV3E). In contrast, we observed binding
of wild-type Parkin with Dac-ubiquitinPhosSer65 with a shift in the size
of the peaks indicating heterodimer formation (Fig EV3F). We also
observed binding of a Parkin S65A mutant with Dac-ubiquitinPhosSer65
(Fig EV3K). Consistent with our ITC data, we observed no evidence
of binding of the Parkin H302A mutant and Dac-ubiquitinPhosSer65 as
judged by two separate peaks (Fig EV3G).
Overall, our binding studies indicate a critical involvement of His302
and Lys151 towards ubiquitinPhospho-Ser65 binding and suggest that these
residuesmay lie within the ubiquitinPhospho-Ser65 binding pocket of Parkin.
Whilst the His302 and Lys 151 residues are not mutated in
human patients with Parkinson’s disease, a number of disease
mutants lie in structural proximity including the RING1 mutant
Arg275Trp (R275W) that we have previously shown to be inactive
[26]. We therefore investigated a panel of disease mutants including
R275W that span all the domains of Parkin for their ability to exhibit
enhancement of phosphorylation of Parkin Ubl Ser65 by PINK1 upon
the addition of ubiquitinPhospho-Ser65. This resulted in the identifica-
tion of three disease mutants K27N, A46P and G430D, of which
K27N and A46P lie within the Ubl domain and G430D lies within
the RING2 domain, that prevented the ability of ubiquitinPhospho-Ser65
to enhance Parkin Ser65 phosphorylation (Fig EV4). However, since
the basal phosphorylation of these proteins in the absence of ubiqui-
tinPhospho-Ser65 was substantially lower than wild-type Parkin, it is
possible that these mutants are trapped in a conformation in which
the Ubl domain is less accessible. Elucidation of the crystal structure
of these mutants in the full-length protein would test this hypothesis
and particularly address how the RING2 mutant G430D that lies
distant from the Ubl-RING1 interface could influence Ubl topology
and Ser65 accessibility. Conversely, the R33Q mutant, which we
previously found to be better phosphorylated than wild-type Parkin
[26] due to presumed disruption of the Ubl domain autoinhibition,
showed only a moderate change in phosphorylation by PINK1 upon
addition of ubiquitinPhospho-Ser65 (Fig EV4).
Evidence that ubiquitinPhospho-Ser65 influences Parkin Ser65
phosphorylation in cells
We next addressed whether mutation of His302 influenced the ability
of Parkin to become phosphorylated at Ser65 in cells upon activation
of PINK1 kinase activity stimulated by CCCP-induced mitochondrial
depolarisation. We expressed wild-type Parkin, a non-phosphorylat-
able S65A mutant and the H302A mutant of Parkin in both wild-type
and PINK1 knockout HeLa cells [27]. Cells were treated with 10 lM
CCCP or DMSO for 6 h, and extracts were immunoblotted with a
phospho-specific antibody raised against a previously characterised
Parkin Ser65 epitope [9] (Fig 4A). Consistent with our in vitro analy-
sis (Fig 2B), the level of Parkin phosphorylation was substantially
diminished in cells expressing H302A Parkin (lanes 7–9, Fig 4A)
compared to wild-type Parkin (lanes 1–3, Fig 4A). The specificity of
the antibody was confirmed by the absence of significant phosphory-
lation in cells expressing S65A Parkin (lanes 4–6, Fig 4A). The strict
dependence of the Parkin Ser65 site on active PINK1 was also
demonstrated by the lack of Parkin phosphorylation at Ser65 in
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PINK1 knockout cells. Under similar conditions, we also investigated
whether His302 was critical for optimal Parkin E3 ligase activity in
cells upon stimulation by mitochondrial depolarisation. Previous
mass spectrometric analysis has identified numerous mitochondrial
proteins as Parkin substrates including the Fe-S cluster-containing
protein CISD1 [25]. Upon stimulation with CCCP, we observed a
clear poly-ubiquitylation of CISD1 in mitochondrial extracts in cells
expressing wild-type but not the catalytic inactive C431F RING2
mutant of Parkin (lane 1 and 4, Fig EV5). Strikingly, we observed a
dramatic reduction in CISD1 poly-ubiquitylation in cells expressing
mutant H302A (lane 3, Fig EV5), suggesting that ubiquitinPhospho-
Ser65 binding to His302 is essential for optimal Parkin activation in
cells and is consistent with our in vitro analysis of the H302A mutant
(Fig 2B–D). We also observed a heavy reduction in CISD1 poly-
ubiquitylation in cells expressing S65A, confirming the critical role
of Ubl Ser65 phosphorylation in the activation of Parkin E3 ligase
activity (lane 2, Fig EV5) in cells.
In parallel, we also undertook immunofluorescence analysis of
Parkin Ser65 phosphorylation in HeLa cells stably over-expressing
wild-type and S65A- or H302A-mutant Parkin. Upon stimulation of
cells expressing wild-type Parkin with 10 lM CCCP, we observed a
striking accumulation of Parkin Ser65 phosphorylation on the mito-
chondria that had undergone peri-nuclear clustering as judged by
staining with the mitochondrial dye Mito-ID Red (top row, Fig 4B).
As predicted with the high specificity of the antibody, we did not
observe any Parkin Ser65 phosphorylation in cells expressing S65A
Parkin following the treatment of CCCP (third row, Fig 4B). Consis-
tent with our Western blot analysis (Fig 4A), we observed a large
reduction of Parkin Ser65 phosphorylation in cells expressing H302A
Parkin. Interestingly, the Ser65-phosphorylated H302A Parkin was
confined mainly to the cytosol (fourth row, Fig 4B).
Overall, our cell-based analysis supports the notion that ubiqui-
tinPhospho-Ser65 binding to Parkin via His302 is required for optimal
phosphorylation of Parkin Ser65 by PINK1 in cells. The diffuse
Parkin H302A Ser65 signal in the cytosol is consistent with Parkin
accumulation to mitochondria being dependent on binding to ubiqui-
tinPhospho-Ser65 [21,28] and suggests a role for ubiquitinPhospho-Ser65
in regulating Parkin retention on the depolarised mitochondria. In
future studies, it would be interesting to undertake time–course analysis
of Parkin phosphorylation and ubiquitylation activity at the mitochon-
dria for wild-type Parkin and the H302A mutant. This may distinguish
between the possibilities of whether H302A is initially phosphorylated
on the mitochondria but cannot be retained over time and whether
there is no Parkin Ubl Ser65 phosphorylation at all on mitochondria due
to its inability to bind ubiquitinPhospho-Ser65 in the first instance.
UbiquitinPhospho-Ser65 disrupts Ubl binding to Parkin
We next investigated the mechanism by which ubiquitinPhospho-Ser65
enhances PINK1-dependent phosphorylation of Parkin Ubl Ser65.
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Figure 6. Purified Parkin phosphorylated at Ser65 exhibits constitutive E3 ligase activity that is no longer sensitive to ubiquitinPhospho-Ser65.
A Parkin phosphorylated at Ser65 exhibits significant constitutive activity. About 2 lg of full-length wild-type (Parkin WT) or phosphorylated at Ser65 (P-Parkin WT)
Parkin was analysed using E3 ligase assay with increasing amounts of non-phospho-ubiquitin or ubiquitinPhospho-Ser65 as indicated. Parkin activity was evaluated by
immunoblotting as follows: ubiquitin (anti-FLAG-HRP antibody), Parkin (anti-Parkin antibody) and Miro1 (anti-SUMO1 antibody). The molecular mass in kDa is
indicated. Data are representative of three independent experiments.
B Dephosphorylation of Parkin at Ser65 leads to reversal of Parkin E3 ligase constitutive activity. About 1 lg of full-length Parkin phosphorylated at Ser65 was subjected
to increasing amounts of alkaline phosphatase as indicated. Reactions were then incubated with ubiquitylation assay components (E1 and UbcH7) in the presence of
0.05 mM FLAG-ubiquitin. Reactions were terminated after 60 min by the addition of LDS loading buffer. The effects on Parkin E3 ligase activity were evaluated by
ubiquitin chain formation ubiquitylation and Parkin autoubiquitylation evaluated by immunoblotting as follows: ubiquitin (anti-FLAG-HRP antibody) and Parkin
(anti-Parkin antibody). The degree of Parkin Ser65 de-phosphorylation was monitored using anti-pSer65 Parkin antibody. Data are representative of four independent
experiments.
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The Ubl domain binds to the RING1 domain [12] and can also inter-
act with Parkin lacking the Ubl domain in trans [11]. Crystal and
NMR solution structures of the Ubl domain reveal that Ser65 resides
in a loop adjacent to the fifth b-strand that exhibits conformational
flexibility [29–31] and may only be partially surface accessible in
the full-length structure. We therefore hypothesised that ubiqui-
tinPhospho-Ser65 binding might disrupt the ability of the Ubl domain to
bind to the C-terminal domain and therefore render Ser65 of the Ubl
domain more accessible for phosphorylation by PINK1.
To address this question, we developed an AlphaScreen in vitro
binding assay to quantify the interaction between Parkin Ubl
domain (GST-Ubl, residues 1-76) and a C-terminal fragment of
Parkin that contains the RING1 domain (Parkin (80-465)-Biotin)
(Fig 5; Appendix Fig S4). Streptavidin-coated donor beads were
used in conjunction with glutathione-coated acceptor beads, and the
binding was established by monitoring proximity-based luminescent
signal. The optimal binding conditions were determined by titrating
GST-Ubl (1-76) 0–300 nM against Parkin (80-465)-biotin 0–300 nM.
Cross-titration analysis revealed optimal binding with concentra-
tions of 10 nM Parkin (80–465)-biotin and 10 nM GST-Ubl (1-76).
Strikingly, we observed that addition of increasing amounts of
ubiquitinPhospho-Ser65 but not non-phospho-ubiquitin led to dose-
dependent disruption of GST-Ubl (1-76) binding to Parkin (80-465)-
biotin with an IC50 of  0.2 nM (Fig 5A and E). This is consistent
with the notion that binding of Parkin to ubiquitinPhospho-Ser65
disrupts the interaction of the Ubl domain with the C-terminal
domain. We next assessed the role of the His302 residue in the
ubiquitinPhospho-Ser65-mediated disruption of Ubl binding. We
observed that the GST-Ubl to Parkin H302A-mutant binding was
insensitive to increasing amounts of ubiquitinPhospho-Ser65 (Fig 5B
and E) consistent with the His302 residue playing an essential role
in binding ubiquitinPhospho-Ser65 and promoting PINK1 phosphorylation
and activation of Parkin (Figs 2 and 3). Consistent with previous
stability analysis of full-length Parkin H302A mutant (Fig EV2A and
B), the E3 ligase activity of Parkin H302A (80-465)-biotin was simi-
lar to wild-type Parkin (Fig EV2B).
To assess the interplay between ubiquitinPhospho-Ser65- and the
Ser65-phosphorylated Ubl domain (UblPhospho-Ser65) moieties in the
activation of Parkin, we undertook AlphaScreen assays using WT
and H302A Parkin and investigated the ability of UblPhospho-Ser65 to
disrupt these interactions. Under similar assay conditions, we
observed that the ability of UblPhospho-Ser65 to disrupt the GST-Ubl to
Parkin WT interaction was greatly reduced compared to
ubiquitinPhospho-Ser65 and the observed mild effect was likely to be
mediated by the presence of unphosphorylated Ubl (< 10%) present
in the UblPhospho-Ser65 sample (Fig 5C and E). This is consistent with
the lack of the effect of UblPhospho-Ser65 in promoting PINK1-dependent
phosphorylation of Parkin (Fig 1C). Similarly, UblPhospho-Ser65 was
only able to weakly disrupt the GST-Ubl to Parkin H302A interaction
(Fig 5D and E) that is again likely to be due to the effect of unphos-
phorylated Ubl in the UblPhospho-Ser65 sample. The elaboration of this
AlphaScreen binding assay also has the potential to identify small
molecules that act as Parkin activators by mimicking the effect of
ubiquitinPhospho-Ser65.
Purified Ser65–phosphorylated Parkin exhibits constitutive
activity that is no longer sensitive to ubiquitinPhospho-Ser65
Our data indicate that binding of ubiquitinPhospho-Ser65 to Parkin may
represent a critical first step of the Parkin activation cascade. This
suggests that the ensuing Parkin Ubl Ser65 phosphorylation by PINK1
is likely to represent the critical effector step leading to the activation
of Parkin E3 ligase activity. To obtain further experimental evidence
for this model, we investigated whether near-maximally phosphorylated
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Figure 7. Priming model of Parkin activation by PINK1-dependent phosphorylation of ubiquitin.
Upon activation of PINK1 by mitochondrial depolarisation, PINK1 can phosphorylate ubiquitin to generate phospho-ubiquitinPhospho-Ser65. Binding of ubiquitinPhospho-Ser65 to
non-phosphorylated Parkin can disrupt intramolecular interaction of Ubiquitin-like (Ubl) domain to Parkin C-terminus. The Ser65 residue on Ubl becomes more accessible for
PINK1-dependent phosphorylation leading to an open and active conformation of Parkin.
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purified Ser65-phosphorylated Parkin (ParkinPhospho-Ser65) could
be further activated by the addition of ubiquitinPhospho-Ser65. His-
SUMO-tagged full-length Parkin was initially captured on Ni-NTA-
agarose, phosphorylated by MBP-TcPINK1, before the His-SUMO tag
was removed and Parkin was purified via nickel affinity and size
exclusion chromatography. Under super-saturating phosphorylation
conditions, we were able to purify a heterogeneous protein
population, wherein approximately 60% Parkin was phosphorylated
as confirmed directly by AQUA peptide analysis (Appendix Fig S5).
We compared the activity of ParkinPhospho-Ser65 with that of wild-
type Parkin in the presence or absence of increasing amounts of
non-phosphorylated ubiquitin or ubiquitinPhospho-Ser65. As expected,
the purified ParkinPhospho-Ser65 exhibited marked E3 ligase activity in
the absence of ubiquitinPhospho-Ser65 as judged by free poly-ubiquitin
chain formation, Miro1 multi-monoubiquitylation and Parkin
autoubiquitylation (Fig 6A). This activity was substantially greater
than the activity observed for wild-type Parkin as evident by Miro1
ubiquitylation. Most importantly, we observed no further enhance-
ment of the activity of ParkinPhospho-Ser65 upon the addition of molar
excess amounts of ubiquitinPhospho-Ser65 that led to maximal activa-
tion of full-length wild-type Parkin (Fig 6A). This was not likely the
result of the ParkinPhospho-Ser65 activity being at saturated levels since
no change was observed when ubiquitinPhospho-Ser65 was added to a
10-fold ParkinPhospho-Ser65 dilution that displayed markedly reduced
constitutive E3 ligase activity (Appendix Fig S6). Furthermore, we
undertook time–course analysis of Parkin E3 ligase activity and
continued to observe no enhancement of ParkinPhospho-Ser65 activity
at 5 min in which the E3 ligase activity of ParkinPhospho-Ser65 had not
reached saturation as judged by free poly-ubiquitin chain formation
and Parkin autoubiquitylation (Appendix Fig S7). We also generated
~90% phosphorylated H302A-mutant Parkin (Appendix Fig S5) and
observed that this was as active as wild-type ParkinPhospho-Ser65
(Appendix Fig S8), providing further evidence that the H302A
mutation is not significantly perturbing the structural fold and integ-
rity of Parkin. To further confirm that the constitutive activity of
ParkinPhospho-Ser65 was indeed due to phosphorylation, we treated
ParkinPhospho-Ser65 with increasing amounts of calf alkaline phospha-
tase and observed a dose-dependent reduction in its activity as
judged by free poly-ubiquitin chain formation and Parkin autoubi-
quitylation that correlated with decreased phosphorylation at Parkin
Ser65 (Fig 6B).
Further structural analysis will be needed to better understand
how ubiquitinPhospho-Ser65 mediates Parkin activation. Currently, it
has been shown that His302 residue lies within the RING1 domain
distal from the Ubl domain [12–14]. Elucidation of the co-complex
of ubiquitinPhospho-Ser65 bound to Parkin in an activated conforma-
tion should define all the key residues on both Parkin and ubiqu-
itinPhospho-Ser65 that are critical for binding and define the molecular role
of the phospho-Ser65-binding pocket in mediating Parkin activation.
Conclusions
Recent models of Parkin activation by PINK1 have highlighted a role
for ubiquitinPhospho-Ser65 in binding and recruiting phosphorylated
Parkin to mitochondria triggering a feed-forward amplification loop
of Parkin activity at the mitochondria [19,21,28]. The data presented
here demonstrate that another major role of ubiquitinPhospho-Ser65 is
to prime Parkin Ubl Ser65 for phosphorylation by PINK1. Further-
more, we have found that once phosphorylated, ParkinPhospho-Ser65
is no longer sensitive to ubiquitinPhospho-Ser65, suggesting that the E3
ligase activity of Parkin may largely be driven by PINK1-mediated
phosphorylation of the Ubl domain of Parkin at Ser65 that may
stabilise it in the active conformation. Our findings elaborate a
2-step model of Parkin activation by ubiquitinPhospho-Ser65 and the
PINK1 kinase (Fig 7) that offers novel insights into how Parkin is
activated and adds another layer of interdependence between Parkin
UblPhospho-Ser65 and ubiquitinPhospho-Ser65 that would be predicted to
drive feed-forward amplification of Parkin E3 ligase activity. Our
findings not only provide fundamental insights into the regulation
of Parkin but also have implications for designing strategies to
search for small molecule activators of Parkin.
Materials and Methods
Materials
[c-32P] ATP was from Perkin Elmer. HaloLink resin was purchased
from Promega. All mutagenesis was carried out using the Quik-
Change site-directed mutagenesis method (Stratagene) with KOD
polymerase (Novagen). All DNA constructs were verified by DNA
sequencing, which was performed by The Sequencing Service,
School of Life Sciences, University of Dundee, using DYEnamic ET
terminator chemistry (Amersham Biosciences) on Applied Bio-
systems automated DNA sequencers. DNA for bacterial protein
expression was transformed into E. coli BL21 DE3 RIL (codon
plus) cells (Stratagene). All cDNA plasmids, antibodies and recom-
binant proteins generated for this study are available to request
through our reagents website (https://mrcppureagents.dun-
dee.ac.uk/).
Antibodies
Antigen affinity-purified sheep anti-SUMO-1 antibody was a kind gift
from Professor Ron Hay (Dundee) (IB: 1:2,000). Anti-Parkin mouse
monoclonal was obtained from Santa Cruz (sc-32282) (IB: 1:5,000;
IF: 1:1,000); anti-FLAG HRP (A8592) (IB: 1:10,000) and anti-actin
(A2066) (IB: 1:5,000) antibodies were obtained from Sigma; anti-
CISD1 (16006-1-AP) (IB: 1:1,000) and anti-TOMM70A (14528-1-AP)
(IB: 1:1,000) antibodies were obtained from Proteintech Europe; and
anti-ubiquitin antibody (Z0458) (IB: 1:1,000) was purchased from
Dako. Epitomics raised anti-Parkin phospho-serine 65 rabbit mono-
clonal antibody in collaboration with the Michael J Fox Foundation
for Research (IB: 1:1,000; IF: 1:500).
Cell culture
HeLa PINK1 knockout cell lines were obtained from Richard Youle
(NIH) and were cultured using DMEM (Dulbecco’s modified Eagle’s
medium) supplemented with 10% FBS (foetal bovine serum), 2 mM
L-glutamine, 1× Pen/Strep and 1× non-essential amino acids (Life
Technologies). Flp-In T-Rex HeLa stable cell lines were cultured in
the above-mentioned media supplemented with 15 lg/ml of blastici-
din and 100 lg/ml of hygromycin. Cell transfections of untagged
Parkin were performed using polyethylene method [32]. To uncouple
ª 2015 The Authors EMBO reports Vol 16 | No 8 | 2015
Agne Kazlauskaite et al Phospho-ubiquitin primes Parkin for activation EMBO reports
949
Published online: June 25, 2015 
mitochondria, cells were treated with 10 lM CCCP (Sigma) dissolved
in DMSO for 6 h.
Membrane fraction enrichment
Cells were collected in ice-cold PBS containing 200 mM chloroaceta-
mide. They were then lysed in buffer containing 250 mM sucrose,
20 mM HEPES, 3 mM EDTA, 1% (w/v) 1 mM sodium orthovana-
date, 10 mM sodium b-glycerophosphate, 50 mM NaF, 5 mM
sodium pyrophosphate, pH 7.5 and protease inhibitor cocktail
(Roche) supplemented with 100 mM chloroacetamide at 4°C. Cells
were disrupted using a glass hand-held homogeniser (40 passes),
and the lysate was clarified by centrifuging for 10 min at 800 g at
4°C. The supernatant was further centrifuged at 16,600 g for
10 min. The pellet containing the mitochondrial fraction was resus-
pended in buffer containing 1% Triton X-100 and centrifuged at
13,000 r.p.m. for 10 min. This supernatant contained solubilised
mitochondrial proteins.
Ubiquitin enrichment in membrane fractions
His-Halo-Ubiquilin UBA-domain tetramer (UBAUBQLN1) was
expressed in E.coli BL21 cells, affinity purified on Ni-NTA-agarose
and dialysed into 50 mM HEPES pH 7.5, 10% glycerol, 150 mM
NaCl and 1 mM DTT. UBAUBQLN1 was coupled to HaloLink Resin as
described in [23]. About 1 mg of mitochondria-enriched fractions
was then subjected to pull-downs as described in [23].
Immunoblotting
Samples were subjected to SDS–PAGE (4–12%) and transferred on
to nitrocellulose membranes. Membranes were blocked for 1 h in
Tris-buffered saline with 0.1% Tween (TBST) containing 5% (w/v)
non-fat dried skimmed milk powder. Membranes were probed with
the indicated antibodies in TBST containing 5% (w/v) non-fat dried
skimmed milk powder overnight at 4°C. Detection was performed
using HRP-conjugated secondary antibodies and enhanced chemilu-
minescence reagent.
Immunofluorescence
HeLa cells stably expressing untagged Parkin WT, S65A or H302A
were plated on glass coverslips and treated as described. Immuno-
fluorescence was performed as described in [33]. Briefly, coverslips
were washed twice with phosphate-buffered saline (PBS), fixed
with 3.7% formaldehyde, 50 mM HEPES pH 7.0 for 10min,
washed twice with and then incubated for 10 min with DMEM,
10 mM HEPES pH 7.4. Cells were permeabilised by incubation
with 0.2% Triton X-100 in PBS followed by two washes and block-
ing for 15 min at RT with PBS supplemented with 1% BSA (PBS/
1% BSA). Cells were stained with the primary antibodies as
follows: ParkinPhospho-Ser65 (1:500) antibody for 16 h at 4°C and
total Parkin antibody (1:1,000) for 1 h at 37°C, followed by anti-
mouse or anti-rabbit Alexa Fluor 405- or Alexa Fluor 488-conju-
gated secondary antibodies (Life Technologies). The mitochondria
was stained using MITO-ID Red detection kit (Enzo Life Sciences)
at for 30 min at 37°C.
Immunofluorescently labelled cells were imaged using the Zeiss
LSM 700 laser scanning confocal microscope with the Alpha
Plan-Apochromat ×100/NA 1.46 objective (optical section thick-
ness 0.7 lm). Parkin-Alexa 405 was excited with the 405 laser,
P-Parkin-Alexa 488 was excited with the 488 laser, and Mitochon-
dria MITO-ID Red was excited with the 555 laser. All labels were
excited independently to prevent cross-channel bleed through.
Analysis of Ser65 phosphorylation of Parkin by AQUA peptides and
mass spectrometry
In order to quantify phosphorylation stoichiometry, 2 ng of Parkin
or phospho-Parkin was digested with trypsin and analysed by abso-
lute quantitation selected reaction monitoring (SRM) LC mass spec-
trometry [34]. Samples were separated by a 60-min gradient on a
50-cm Acclaim PepMap 100 analytical column (75 lm ID, 3 lm C18) in
conjunction with a PepMap trapping column (100 lm × 2 cm, 5 lm
C18) (Thermo Fisher Scientific) in a Dionex Ultimate 3000 Nano LC
system (Dionex/Thermo Fisher) coupled to a QTRAP 5500 (ABS-
CIEX) mass spectrometer. Synthetic peptides were used to define
retention time and the optimal 10 transitions per peptide, based on
optimal intensity of precursor charge state and fragment ions. One
pmol of heavy labelled peptides of Parkin NDWTVQN[C(CAM)]
DLDQQSIVHIVQRPW[R(13C6; 15N4)], R.NDWTVQN[C(CAM)]
DLDQQ[S(PO3H2)]IVHIVQRPWR(13C6; 15N4)] (AQUA QuantPro,
Thermo Scientific) was mixed with the trypsin digest of phospho-
Parkin, and the ratio of peak intensities of ten distinct transitions for
light (endogenous) and heavy peptides was used to calculate the
amount of endogenous proteins. Data were analysed with Skyline
software [35].
In vitro ubiquitylation assays
Wild-type ParkinPhospho-Ser65 or indicated mutant of Parkin (2 lg or
0.2 lg) was incubated with ubiquitylation assay components in a
final volume of 50 ll (50 mM Tris–HCl (pH 7.5), 5 mM MgCl2,
0.12 lM UbE1, 1 lM UbcH7 and 2 lg 6xHis-Sumo-Miro, 2 mM
ATP). About 5 lg of ubiquitin or ubiquitinPhospho-Ser65 was added as
indicated. Ubiquitylation reactions were incubated at 30°C for
60 min and terminated by the addition of LDS sample buffer. For all
assays, reaction mixtures were resolved by SDS–PAGE. Ubiquityla-
tion reactions were subjected to immunoblotting with anti-FLAG
antibody (Sigma, 1:10,000), anti-Parkin (Santa Cruz 1:5,000) or
anti-SUMO1 (1:2,000).
In vitro E2 discharge assays
E2-charging reaction was assembled in 5 ll containing Ube1
(0.5 lg), an UbcH7 (2 lg), 50 mM HEPES pH 7.5 and 10 lM ubiqui-
tin in the presence of 2 mM magnesium acetate and 0.2 mM
ATP. After initial incubation of 60 min at 30°C, the reactions were
combined with 2 lg of WT or indicated mutant of Parkin in the
presence or absence of 1 lg of ubiquitin or ubiquitinPhospho-Ser65 and
allowed to continue for a further 15 min at 30°C. Reactions were
terminated by the addition of 5 ll of LDS loading buffer and
subjected to SDS–PAGE analysis in the absence of any reducing
agent. Gels were stained using InstantBlue.
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Kinase assays
Reactions were set up in a volume of 25 ll, using 2 lg of WT or
indicated mutants of Parkin and 1 lg of wild-type or kinase-inactive
(D359A) MBP-TcPINK1, in 50 mM Tris–HCl (pH 7.5), 0.1 mM
EGTA, 10 mM MgCl2, 0.1% b-mercaptoethanol and 0.1 mM [c-
32P]
ATP. About 1 lg of different ubiquitin species or indicated amounts
of WT, S65A or ubiquitinPhospho-Ser65 was added as indicated. Assays
were incubated at 30°C and terminated after 60 min by the addition
of SDS sample loading buffer. The reaction mixtures were then
resolved by SDS–PAGE. Proteins were detected by Coomassie stain-
ing, and gels were imaged using an Epson scanner and dried
completely using a gel dryer (Bio-Rad). Incorporation of [c-32P] ATP
into substrates was analysed by autoradiography using Amersham
Hyper-Film.
Buffers for E. coli protein purification
For Parkin purification, lysis buffer contained 50 mM Tris–HCl (pH
7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5% (v/v) glycerol,
1% (v/v) Triton X-100, 0.1% (v/v) 2-mercaptoethanol, 1 mM benz-
amidine and 0.1 mM PMSF. Wash buffer contained 50 mM Tris–
HCl (pH 7.5), 500 mM NaCl, 0.1 mM EGTA, 5% (v/v) glycerol,
0.03% (v/v) Brij-35, 0.1% (v/v) 2-mercaptoethanol, 1 mM benz-
amidine and 0.1 mM PMSF. Equilibration buffer contained 50 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 0.1 mM EGTA, 5% (v/v) glycerol,
0.03% (v/v) Brij-35, 0.1% (v/v) 2-mercaptoethanol, 1 mM benz-
amidine and 0.1 mM PMSF. Elution buffer was equilibration buffer
with the addition of 12 mM maltose. Storage buffer was equilibra-
tion buffer with the addition of 0.27 M sucrose and glycerol—PMSF
and benzamidine were omitted.
Protein purification from E. coli
Full-length, wild-type and kinase-inactive TcPINK1 was expressed
in E. coli as maltose-binding protein (MBP) fusion protein and puri-
fied as described previously [36]. Briefly, BL21 CodonPlus-
transformed cells were grown at 37°C to an OD600 of 0.3, then
shifted to 16°C and induced with 250 lM IPTG (isopropyl b-D-thio-
galactoside) at OD600 of 0.5. Cells were induced with 250 lM IPTG
at OD 0.6 and were further grown at 16°C for 16 h. Cells were
pelleted at 4,000 rpm and then lysed by sonication in lysis buffer.
Lysates were clarified by centrifugation at 30,000 g for 30 min at
4°C followed by incubation with 1 ml per litre of culture of amylose
resin for 1.5 h at 4°C. The resin was washed thoroughly in wash
buffer and then equilibration buffer, and proteins were then eluted.
Proteins were dialysed overnight at 4°C into storage buffer, snap-
frozen and stored at 80°C until use.
Wild-type and indicated mutant untagged Parkin (His-SUMO
cleaved) was expressed and purified using a modified protocol as
previously described [18].
Ser65-phosphorylated Parkin was produced by the expression of
His-SUMO-tagged Parkin and then captured by Ni2+-NTA-Sepharose
as described above. After extensive washes, captured His-SUMO-
Parkin was incubated with MBP-PINK (Parkin: PINK1 ratio of 2:1)
twice consecutively for 3 h in the presence of 0.5 mM ATP and
10 mM Mg-acetate at 27°C. PINK1 was removed, and Parkin was
eluted with 0.4 M imidazole and further incubated for 16 h with
MBP-PINK1 in solution. The proteins were concentrated using Viva-
spin filters and then diluted again to reduce the imidazole concen-
tration to 20 mM to recapture His-SUMO-Parkin on Ni-agarose.
Residual MBP-PINK1 was removed by extensive washes, before
His-SUMO-Parkin was eluted with 0.4 M imidazole and further puri-
fied as described above.
Wild-type 6xHis-Sumo-Miro1 (1–592) was expressed in E. coli.
Briefly, BL21 CodonPlus (DES)-RIL-transformed cells were grown at
37°C to an OD600 of 0.4, then reduced to 15°C and induced with
10 lM IPTG at an OD600 of 0.6. Cells were then grown at 15°C for a
further 20 h. Cells were pelleted at 4,200 g and then lysed by soni-
cation in lysis buffer. Lysates were clarified by centrifugation at
30,000 g for 30 min at 4°C followed by incubation with cobalt resin
at 4°C for 45 min. The resin was washed thoroughly in high salt
buffer and equilibrated in low salt buffer, and the proteins were
then eluted. The eluted Miro1 proteins were further purified by
anion exchange chromatography. Proteins were applied to a Mono-
Q HR 5/5 column and chromatographed with a linear gradient of
NaCl from 0 M to 0.5 M. Fractions containing the purified Miro1
protein were then dialysed, snap-frozen in liquid nitrogen and
stored at 70°C.
Purification of Ser65-phosphorylated ubiquitin and Ser65-
phosphorylated Parkin Ubl domain (residues 1-76)
About 23 lM bovine ubiquitin (SIGMA) was phosphorylated for
24 h with 3.7 lM MBP-PINK1 at 22°C in the presence of 100 lM
ATP and 10 mM MgCl2. To replace ADP with ATP, the reaction
was dialysed against Mg-ATP solution. Ubiquitin was filtered
through a 30-kDa Vivaspin filter to remove MBP-PINK1, concen-
trated in a 3-kDa MWCO filter device, washed extensively with
water and loaded onto a Mono-Q column, which did not bind
ubiquitin, but phospho-ubiquitin. The latter was recovered by
washing the column with 50 mM Tris pH 7.5, which was sufficient
to elute stoichiometrically phosphorylated ubiquitin. Similarly,
Parkin Ubl domain (residues 1-76) was expressed as previously
described [9] and was phosphorylated with MBP-TcPINK1, recov-
ered by filtration and applied to a Mono-Q column. Phospho-Parkin
Ubl bound to the column and eluted with about 100 mM NaCl. At
least, 90% purity was achieved.
Purification of Dac-ubiquitin and
Ser65-phosphorylated Dac-ubiquitin
The Dac tag is a fragment of E. coli penicillin-binding Protein 5,
comprising residues 37-297, where the N-terminus was modified to
MSAIPG to allow efficient mRNA translation [24]. pET28-Dac-ubiqu-
itin was transformed into BL21 cells. Protein expression was
induced with 250 lM IPTG for 16 h at 26°C. Cells were sedimented
and lysed in 50 mM Tris pH 7.5, 0.5% Triton X-100, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM Pefabloc and 10 lg/ml leupeptin. After
sonication, the insoluble material was removed by centrifugation.
Dac-ubiquitin fusion protein was captured by incubation for 45 min
at 22°C with ampicillin-Sepharose. The ampicillin-Sepharose was
thoroughly washed, and the protein was eluted with 50 mM Tris pH
7.5, 150 mM NaCl, 5% glycerol, 10 mM ampicillin and 0.03%
Brij35. The protein was dialysed into 40 mM HEPES, pH 7.5,
100 mM NaCl and 1 mM DTT.
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Ser65-phosphorylated Dac-ubiquitin (Dac-ubiquitinPhosSer65) was
prepared by phosphorylation of Dac-ubiquitin with GST-Pediculus
humanus PINK1 126-end (ratio Dac-Ub: GST PhPINK of 6.25:1) for
3 h in the presence of 20 mM Mg-acetate and 2 mM ATP.
Dac-ubiquitin was repurified over ampicillin-Sepharose and concen-
trated to match the concentration of Dac-ubiquitin.
Gel filtration chromatography analysis of complexes
A Superdex 200 Increase 10/300 GL column (GE Healthcare Life
Sciences) was equilibrated with 50 mM Tris pH 7.5 and 150 mM
NaCl. The proteins: 100 lg of Dac-ubiquitin, Dac-ubiquitinPhosSer65,
Parkin (1-465), Parkin 1-465 S65A, or Parkin 1-465 H302A or
mixtures thereof, were made and subjected to chromatography on
the column at a flowrate of 0.3 ml/min. Mixtures were incubated
for 30 min prior to chromatography. The elution of the proteins was
monitored by UV absorption at 280 nm.
MALDI analysis
MALDI-TOF was used to confirm and establish the ratios of phos-
phorylated versus non-phosphorylated protein species. An aliquot
of the reaction (2 ll, 400–600 fmols) was added to 2 ll of the matrix
(2,5-dihydroxyacetophenone, 15 mg/ml in 80% ethanol, 20% of
12 mg/ml ammonium citrate bibasic), and 2 ll of 2% (v/v) trifluo-
roacetic acid was added before spotting 0.5 ll of the sample on to
an AnchorChip target (Bruker Daltonics). The analysis was
performed manually in linear positive mode using an UltrafleXtreme
(Bruker Daltonics) MALDI–TOF mass spectrometer. For external
calibration, six average masses were used: insulin [M+H]+ avg (m/z
5734.520), cytochrome c [M+2H]2+ avg (m/z 6181.050), myoglobin
[M+2H]2+ avg (m/z 8476.660), ubiquitin I [M+H]+ avg (m/z
8565.760) and cytochrome C [M+H]+ avg (m/z 12360.970).
AlphaScreen binding assay
Serial three-fold, 10-point dilution curves of inhibitor proteins
ubiquitinPhosSer65 and ubiquitin were prepared in PBS + 0.1% BSA +
0.1% Triton X-100 with a maximum concentration of 400 nM. Simi-
lar three-fold 10-point dilution curves of UblPhosSer65 and Ubl were
produced with a maximum concentration of 24.7 mM. Biotinylated
wild-type or H302A-mutant Parkin protein and GST-Ubl were
diluted to 40 nM in PBS + 0.1% BSA +0.1% Triton X-100. 5 ll of
inhibitor, 5 ll of GST-Ubl and 5 ll of Parkin protein were added to
a white-walled 384-well plate (Griener Bio-one). Plates were centri-
fuged at 500 g for 3 min and mixed on an orbital shaker at 450 rpm
for 3 min prior to incubation at RT for 20 min. About 5 ll of a
20 lg/ml mixture of streptavidin donor and glutathione acceptor
beads in PBS + 0.1% BSA + 0.1% Triton X-100 was added to all
wells. Plates were briefly centrifuged and incubated at RT in the
dark for 1 h prior to reading on PHERAstar (BMG LABTECH) using
an AlphaLISA optical module (excitation wavelength = 680 nm and
emission wavelength = 615 nm).
Isothermal calorimetric assay
ITC measurements were carried out on an ITC200 Microcalorimeter
(GE Healthcare). Wild-type, and His302Ala- and Lys151Ala-mutant
Parkin and ubiquitinPhosSer65 were dialysed in buffer containing
50 mM HEPES (pH 8.0), 150 mM NaCl and 500 lM of TCEP. The
sample cell containing 50 lM of wild-type or mutant Parkin and
sufficient amount of ubiquitinPhosSer65 was titrated in the injection
syringe to achieve a complete binding isotherm. All binding experi-
ments were undertaken in duplicate at constant temperature of
20°C. A total of 20 injections of 2.0 ll were dispensed with a 5-s
addition time and spacing of 120 s. Data were analysed and titration
curves fitted using MicroCal Origin software assuming a single bind-
ing site mode.
Thermal shift assay
Thermal denaturation experiments were performed using Differen-
tial Scanning Fluorimetry (DSF). 5 lg of wild-type, and His302Ala-
or Lys151Ala-mutant Parkin protein was added to 45 ll reaction
buffer (50 mM Hepes pH 8.0, 150 mM NaCl, 500 lM TCEP) and
2.5 ll of 100× Sypro Orange (Invitrogen) fluorescent dye to yield a
final reaction volume of 50 ll. Each experiment was repeated three
times in a 96-well plate in a Bio-Rad iQ5 thermal cycler, with a
temperature gradient set from 10°C to 95°C at steps of 0.5°C per
min.
Expanded View for this article is available online:
http://embor.embopress.org
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